HOMA-IR is not a standalone lab test, so its cost is the cost of the two tests behind it, fasting glucose and fasting insulin, plus the draw and the reporting. Price depends on the panel it sits in, the lab, and whether it is bundled with other markers. The current price is shown with the panel details on this page.
Because the score is a calculation rather than an assay, there is nothing extra to run once those two fasting values exist. That is why insulin resistance testing is nearly always priced as a panel rather than as a line item. The Metabolic + Insulin panel groups the fasting pair with the related markers a clinician reads alongside them, and it is HSA/FSA eligible.
HOMA-IR, short for homeostatic model assessment of insulin resistance, is a single number calculated from fasting glucose and fasting insulin that estimates how much insulin the body is producing to keep blood sugar steady.
The arithmetic is simple. The two fasting values are multiplied, then divided by a fixed constant that depends on the units the lab reports. Nothing is measured directly. There is no separate tube and no separate assay, because the lab or the platform computes the figure from results it already holds.
That matters in a practical way when you are comparing prices. If someone quotes you for a HOMA-IR test, they are quoting you for fasting glucose plus fasting insulin. Glucose is a routine chemistry measurement that appears on almost every basic metabolic panel. Fasting insulin is an immunoassay, ordered far less often, and it is usually the component that explains why a metabolic panel with insulin costs more than one without it.
HOMA-IR is widely used as a practical surrogate for more demanding laboratory methods of assessing insulin sensitivity, and reviews note that the thresholds used to flag a result differ across populations and assays 1.
Lab pricing is less mysterious than it looks. A small number of variables move it, and most of them are visible before you book.
| What moves the price | Why it matters |
|---|---|
| Number of markers | Every additional analyte adds reagent and processing cost, though bundled panels usually cost less per marker than single add-ons. |
| Assay complexity | A routine chemistry measurement like glucose is cheaper to run than an immunoassay like fasting insulin. |
| Panel versus single add-on | Markers ordered one at a time are typically priced higher per marker than the same markers inside a panel built around a question. |
| Where the blood is drawn | A clinic draw, a partner draw site and a mobile phlebotomy visit each carry different collection costs. |
| Whether interpretation is included | Some prices cover the assay only. Others include a written interpretation or clinician review, which is part of what you are buying. |
| Self-pay versus billing a plan | A self-pay catalogue price and a price processed through a health plan are set in different ways, and the amount you owe can differ. |
| How often you retest | A one-off draw and a repeating testing schedule inside a membership are priced on different logic. |
Two further points are worth knowing. First, an insulin resistance workup is rarely useful in isolation, so most of what you pay buys context rather than the single number. Second, the cheapest possible draw is not always the better value if the result arrives with no reference framing and no plan for what to recheck later.
FitScript is a labs-first membership, so testing is the starting point rather than an upsell. The Metabolic + Insulin panel is built around the fasting pair that HOMA-IR is derived from, together with the related metabolic markers that make the number interpretable. The full marker list and the current price are shown with the panel details on this page.
Membership testing runs across the year rather than as a single snapshot, with 150+ biomarkers tested per year, so a metabolic result can be compared against a prior draw instead of being read in isolation. Results are interpreted by Atlas, the AI health advisor that reads your markers in context, and anything that might call for treatment is reviewed by a licensed provider who decides what, if anything, is appropriate.
If you already have recent fasting glucose and fasting insulin from another lab, the score can be calculated from those two values. The usual catch is that fasting insulin is not included on standard metabolic panels, so most people find they have the glucose and not the insulin.
Coverage varies by plan and by the reason the test is ordered, so the only reliable answer comes from your own plan. Some plans treat fasting insulin as covered when it is ordered to investigate a specific clinical concern and as non-covered when it is ordered for general screening or optimization. Call the number on your card, ask about the specific tests rather than the HOMA-IR label, and ask how the ordering reason affects the answer.
The panel is HSA/FSA eligible, which is a separate question from insurance coverage. Eligibility means you can generally pay with those pre-tax funds. It does not mean a plan will reimburse the cost.
The panel is a fasting draw, so schedule it for the morning and follow the fasting instructions supplied with your booking rather than a general rule you read elsewhere. Water is usually allowed. The rest of the preparation is about not making the day unusual.
Keep your eating and training in the days before the draw close to your normal pattern, since a sharp departure from routine makes the result harder to compare against your last one. Tell the ordering clinician about any medications or supplements you take, because several can influence glucose or insulin and the interpretation changes if they are unknown. If you are acutely unwell, it is reasonable to ask whether to reschedule.
The two inputs are read first, then the calculated score, then all of it against the rest of the panel.
| Marker | Typical lab reference range | Units |
|---|---|---|
| Fasting glucose | roughly 70 to 99 | mg/dL |
| Fasting insulin | varies widely by assay, often roughly 2 to 25 | µIU/mL |
| HOMA-IR | no single universally agreed cut-off, read against the reporting lab's reference population | calculated value |
These are typical lab reference ranges, and they vary by lab, assay, age and sex. They are not optimization targets and they are not diagnostic cut-offs on their own.
A worked way to think about it. The observation is a fasting insulin sitting in the upper part of the range while fasting glucose still reads mid-range. What it may reflect is the body producing more insulin to hold glucose where it is, which is the pattern the score is designed to surface. What it is worth doing is bringing the full panel, the trend across draws and your symptoms to a clinician, who can decide whether anything further is warranted. A suboptimal or out of range value is never a diagnosis by itself, and a result that looks clearly outside the standard range is worth discussing with a clinician promptly rather than filing away.
It cannot tell you that you have a condition. HOMA-IR is an estimate built from two fasting values taken on one morning, and reviews of its use describe the difficulty of setting diagnostic thresholds that hold across different populations and assay methods 1.
It also says nothing about what happens after a meal, which is a different question from fasting physiology. And it does not identify a cause. Insulin resistance in polycystic ovary syndrome, for example, has been described as differing across phenotypes within the same condition 2. A large meta-analysis of metabolic parameters reported that depression is associated with differences in measures including insulin resistance 3. The same score can sit behind very different situations, which is exactly why interpretation belongs with a clinician who can see the whole person.
Movement is the most consistently examined lever. A systematic review and meta-analysis found that exercise training is associated with improvements in insulin resistance in adults with type 2 diabetes 4. Research suggests that, in children and adolescents with excess weight, exercise interventions improve insulin resistance markers compared with control conditions 5.
Diet is the other heavily studied area. A recent review of nutrition and insulin resistance describes dietary patterns as a central target in its pathophysiology 6. A systematic review and meta-analysis reported that adjusting dietary carbohydrate intake may help glycaemic control and insulin resistance measures in type 2 diabetes 7. Intermittent fasting has been examined in metabolic syndrome, with a GRADE assessed review reporting effects on insulin resistance, lipid profile and inflammation 8. Diet has also been studied specifically in polycystic ovary syndrome, where insulin resistance is a common feature 9.
None of that replaces an individual assessment, and this page does not cover treatment. Where a treatment is appropriate, a licensed provider evaluates that after reviewing your history, your examination and your labs.
This page is educational and is not medical advice. Discuss your results, and any treatment, with a clinician or licensed provider who can see your full picture.
To see the markers, the collection options and the current price together, open the Metabolic + Insulin panel, and read the marker background on the HOMA-IR page before you book.
No. It is a calculation, not an assay. The score comes from fasting glucose and fasting insulin, so what you are buying is those two measurements plus the blood draw. Once both values exist, the score is computed from them with no extra sample required.
Because a lone number is hard to act on. Fasting insulin is rarely informative without glucose and the surrounding metabolic markers, and markers ordered individually are usually priced higher per marker than the same markers inside a panel. The current price is shown with the panel details on this page.
Yes, the Metabolic + Insulin panel is marked HSA or FSA eligible, so those pre-tax funds can generally be used. Eligibility is a separate question from insurance reimbursement, so confirm the rules of your own account administrator if you are unsure.
Coverage varies by plan and by why the test was ordered, so check directly with your plan. Ask about the individual tests, fasting glucose and fasting insulin, rather than the HOMA-IR label, and ask whether the ordering reason changes the answer.
Yes, both inputs are fasting measurements, so the panel is a fasting draw. Follow the specific fasting instructions supplied with your booking rather than a general rule, schedule the appointment for the morning, and keep your routine in the preceding days close to normal.
That depends on your situation and is a decision for the clinician reviewing your results. The value of the number rises when you can compare it against a previous draw taken under similar conditions, which is why repeat testing on a consistent schedule is more useful than a single snapshot.
Treat it as information, not a verdict. A value outside the standard range is worth discussing with a clinician, who can read it next to your other markers, your history and your symptoms. A result that looks clearly out of range is worth raising promptly rather than setting aside.
If that report includes both fasting glucose and fasting insulin from the same draw, yes. The usual obstacle is that standard metabolic panels include glucose but not insulin, so most older reports have only half of what the calculation needs.
Not by itself. The calculation reflects fasting physiology on one morning and says nothing about how you handle a meal or what happens over time. It is one input among many, and a clinician reads it alongside the rest of your panel.